These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20040702)

  • 1. Integrase inhibitors: a novel class of antiretroviral agents.
    Schafer JJ; Squires KE
    Ann Pharmacother; 2010 Jan; 44(1):145-56. PubMed ID: 20040702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Tolerability of Integrase Inhibitors in Antiretroviral-Naive Patients.
    D'Abbraccio M; Busto A; De Marco M; Figoni M; Maddaloni A; Abrescia N
    AIDS Rev; 2015; 17(3):171-85. PubMed ID: 26450805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Integrase inhibitors - new challenges for the treatment of HIV-1 infections].
    Stock I
    Med Monatsschr Pharm; 2013 Dec; 36(12):448-59; quiz 461-2. PubMed ID: 24450269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
    Kulkarni R; Hluhanich R; McColl DM; Miller MD; White KL
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6145-50. PubMed ID: 25092710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elvitegravir: a once-daily inhibitor of HIV-1 integrase.
    Wills T; Vega V
    Expert Opin Investig Drugs; 2012 Mar; 21(3):395-401. PubMed ID: 22321026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation integrase inhibitors : where to after raltegravir?
    Karmon SL; Markowitz M
    Drugs; 2013 Mar; 73(3):213-28. PubMed ID: 23413196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
    Lennox JL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
    Correll T; Klibanov OM
    Pharmacotherapy; 2008 Jan; 28(1):90-101. PubMed ID: 18154479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
    Olin JL; Spooner LM; Klibanov OM
    Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results.
    Elion R; Molina JM; Ramón Arribas López J; Cooper D; Maggiolo F; Wilkins E; Conway B; Liu YP; Margot N; Rhee M; Chuck SL; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):494-7. PubMed ID: 23807156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elvitegravir: a review of its use in adults with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Apr; 74(6):687-97. PubMed ID: 24671908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
    Lampiris HW
    Expert Rev Anti Infect Ther; 2012 Jan; 10(1):13-20. PubMed ID: 22149610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on raltegravir and the development of new integrase strand transfer inhibitors.
    Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
    South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.